{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:28:06Z","timestamp":1782890886793,"version":"3.54.5"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11899-020-00559-4","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T09:04:05Z","timestamp":1580461445000},"page":"31-43","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Novel Treatment Strategies in the Management of Waldenstr\u00f6m Macroglobulinemia"],"prefix":"10.1007","volume":"15","author":[{"given":"Saurabh","family":"Zanwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jithma Prasad","family":"Abeykoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"issue":"Suppl 1","key":"559_CR1","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1179\/102453312X13336169156212","volume":"17","author":"MA Gertz","year":"2012","unstructured":"Gertz MA. Waldenstrom macroglobulinemia. Hematology. 2012;17(Suppl 1):S112\u20136.","journal-title":"Hematology"},{"issue":"5","key":"559_CR2","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjh.14266","volume":"179","author":"JG Correa","year":"2017","unstructured":"Correa JG, Cibeira MT, Tovar N, Isola I, Pedrosa F, Diaz T, et al. Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstrom macroglobulinaemia. Br J Haematol. 2017;179(5):849\u201351.","journal-title":"Br J Haematol"},{"issue":"16","key":"559_CR3","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.19.00394","volume":"37","author":"M Bustoros","year":"2019","unstructured":"Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, et al. Progression risk stratification of asymptomatic Waldenstrom macroglobulinemia. J Clin Oncol. 2019;37(16):1403\u201311.","journal-title":"J Clin Oncol"},{"issue":"2","key":"559_CR4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/sonc.2003.50038","volume":"30","author":"Robert A. Kyle","year":"2003","unstructured":"Kyle RA, Treon SP, Alexanian R, Barlogie B, Bj\u00f6rkholm M, Dhodapkar M, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia. Semin Oncol. 2003;30(2):116\u201320.","journal-title":"Seminars in Oncology"},{"issue":"3","key":"559_CR5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bjh.14881","volume":"179","author":"E Durot","year":"2017","unstructured":"Durot E, Tomowiak C, Michallet AS, Dupuis J, Hivert B, Lepretre S, et al. Transformed Waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO). Br J Haematol. 2017;179(3):439\u201348.","journal-title":"Br J Haematol"},{"issue":"3","key":"559_CR6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41375-018-0286-7","volume":"33","author":"Saurabh Zanwar","year":"2018","unstructured":"Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, et al. Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia. Leukemia. 2019;33(3):790\u20134.","journal-title":"Leukemia"},{"key":"559_CR7","doi-asserted-by":"crossref","unstructured":"Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, et al. Impact of MYD88(L265P) mutation status on histological transformation of Waldenstrom macroglobulinemia. Am J Hematol. 2019.","DOI":"10.1002\/ajh.25697"},{"key":"559_CR8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/CMAR.S94059","volume":"9","author":"JP Abeykoon","year":"2017","unstructured":"Abeykoon JP, Yanamandra U, Kapoor P. New developments in the management of Waldenstrom macroglobulinemia. Cancer Manag Res. 2017;9:73\u201383.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"559_CR9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2012.44.7920","volume":"31","author":"V\u00e9ronique Leblond","year":"2013","unstructured":"Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31(3):301\u20137.","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"559_CR10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cncr.26303","volume":"118","author":"Alessandra Tedeschi","year":"2011","unstructured":"Tedeschi A, Benevolo G, Varettoni M, Battista ML, Zinzani PL, Visco C, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer. 2012;118(2):434\u201343.","journal-title":"Cancer"},{"issue":"1","key":"559_CR11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/leu.2008.261","volume":"23","author":"C Buske","year":"2008","unstructured":"Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23(1):153\u201361.","journal-title":"Leukemia"},{"issue":"2","key":"559_CR12","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1200\/JCO.2007.15.1530","volume":"27","author":"Xavier Leleu","year":"2009","unstructured":"Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, et al. Increased incidence of transformation and myelodysplasia\/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27(2):250\u20135.","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"559_CR13","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","volume":"3","author":"P Kapoor","year":"2017","unstructured":"Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, et al. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol. 2017;3(9):1257\u201365.","journal-title":"JAMA Oncol"},{"issue":"9","key":"559_CR14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstrom\u2019s macroglobulinemia. N Engl J Med. 2012;367(9):826\u201333.","journal-title":"N Engl J Med"},{"issue":"13","key":"559_CR15","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","volume":"121","author":"Marzia Varettoni","year":"2013","unstructured":"Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom\u2019s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121(13):2522\u20138.","journal-title":"Blood"},{"issue":"2","key":"559_CR16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajh.24955","volume":"93","author":"Jithma P. Abeykoon","year":"2017","unstructured":"Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, et al. MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia. Am J Hematol. 2018;93(2):187\u201394.","journal-title":"American Journal of Hematology"},{"issue":"10","key":"559_CR17","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-18-0215","volume":"78","author":"Xinfang Yu","year":"2018","unstructured":"Yu X, Li W, Deng Q, Li L, Hsi ED, Young KH, et al. MYD88 L265P mutation in lymphoid malignancies. Cancer Res. 2018;78(10):2457\u201362.","journal-title":"Cancer Research"},{"issue":"1","key":"559_CR18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","volume":"228","author":"AJ Mohamed","year":"2009","unstructured":"Mohamed AJ, Yu L, Backesjo CM, Vargas L, Faryal R, Aints A, et al. Bruton\u2019s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228(1):58\u201373.","journal-title":"Immunol Rev"},{"issue":"25","key":"559_CR19","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1182\/blood-2016-01-695098","volume":"127","author":"Guang Yang","year":"2016","unstructured":"Yang G, Buhrlage SJ, Tan L, Liu X, Chen J, Xu L, et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016;127(25):3237\u201352.","journal-title":"Blood"},{"issue":"9","key":"559_CR20","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.4049\/jimmunol.159.9.4322","volume":"159","author":"M Moriuchi","year":"1997","unstructured":"Moriuchi M, Moriuchi H, Turner W, Fauci AS. Cloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entry. J Immunol. 1997;159(9):4322\u20139.","journal-title":"J Immunol"},{"issue":"2","key":"559_CR21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0014-5793(98)00359-7","volume":"426","author":"A. Caruz","year":"1998","unstructured":"Caruz A, Samsom M, Alonso JM, Alcami J, Baleux F, Virelizier JL, et al. Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett. 1998;426(2):271\u20138.","journal-title":"FEBS Letters"},{"issue":"11","key":"559_CR22","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","volume":"123","author":"Zachary R. Hunter","year":"2014","unstructured":"Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637\u201346.","journal-title":"Blood"},{"issue":"18","key":"559_CR23","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","volume":"123","author":"SP Treon","year":"2014","unstructured":"Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123(18):2791\u20136.","journal-title":"Blood."},{"key":"559_CR24","doi-asserted-by":"crossref","unstructured":"Xu L, Hunter ZR, Tsakmaklis N, Cao Y, Yang G, Chen J, et al. Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom macroglobulinaemia. Br J Haematol. 2016;172(5):735\u201344.","DOI":"10.1111\/bjh.13897"},{"issue":"26","key":"559_CR25","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1182\/blood-2014-03-564583","volume":"123","author":"Aldo M. Roccaro","year":"2014","unstructured":"Roccaro AM, Sacco A, Jimenez C, Maiso P, Moschetta M, Mishima Y, et al. C1013G\/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014;123(26):4120\u201331.","journal-title":"Blood"},{"issue":"25","key":"559_CR26","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","volume":"378","author":"Meletios A. Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Tedeschi A, Trotman J, Garc\u00eda-Sanz R, Macdonald D, Leblond V, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2018;378(25):2399\u2013410.","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"559_CR27","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.3109\/10428194.2015.1012714","volume":"56","author":"Alessandra Tedeschi","year":"2015","unstructured":"Tedeschi A, Picardi P, Ferrero S, Benevolo G, Margiotta Casaluci G, Varettoni M, et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2015;56(9):2637\u201342.","journal-title":"Leukemia & Lymphoma"},{"issue":"9873","key":"559_CR28","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"Mathias J Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310.","journal-title":"The Lancet"},{"issue":"2","key":"559_CR29","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","volume":"7","author":"Roger G Owen","year":"2020","unstructured":"Owen RG, McCarthy H, Rule S, D'Sa S, Thomas SK, Tournilhac O, et al. Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol 2020;7(2);e112\u2013121. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S2352302619302108","journal-title":"The Lancet Haematology"},{"issue":"1","key":"559_CR30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjh.15718","volume":"186","author":"K Laribi","year":"2019","unstructured":"Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, et al. Bendamustine plus rituximab in newly-diagnosed Waldenstrom macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol. 2019;186(1):146\u20139.","journal-title":"Br J Haematol"},{"issue":"11","key":"559_CR31","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","volume":"126","author":"Efstathios Kastritis","year":"2015","unstructured":"Kastritis E, Gavriatopoulou M, Kyrtsonis M-C, Roussou M, Hadjiharissi E, Symeonidis A, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstr\u00f6m macroglobulinemia: final analysis of a phase 2 study. Blood. 2015;126(11):1392\u20134.","journal-title":"Blood"},{"issue":"15_suppl","key":"559_CR32","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1200\/JCO.2019.37.15_suppl.7509","volume":"37","author":"JP Abeykoon","year":"2019","unstructured":"Abeykoon JP, Zanwar S, Ansell SM, Kumar S, Thompson CA, Habermann TM, et al. Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM). J Clin Oncol. 2019;37(15_suppl):7509.","journal-title":"J Clin Oncol"},{"issue":"1","key":"559_CR33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.15148","volume":"181","author":"Jorge J. Castillo","year":"2018","unstructured":"Castillo JJ, Gustine JN, Meid K, Dubeau TE, Severns P, Xu L, et al. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstrom macroglobulinaemia. Br J Haematol. 2018;181(1):77\u201385.","journal-title":"British Journal of Haematology"},{"issue":"8","key":"559_CR34","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00277-018-3311-z","volume":"97","author":"Jonas Paludo","year":"2018","unstructured":"Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia. Ann Hematol. 2018;97(8):1417\u201325.","journal-title":"Annals of Hematology"},{"issue":"Supplement_1","key":"559_CR35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2019-121909","volume":"134","author":"MJ Rummel","year":"2019","unstructured":"Rummel MJ, Lerchenm\u00fcller C, Hensel M, Goerner M, Buske C, Schulz H, et al. Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with Waldenstr\u00f6m\u2019s macroglobulinemia (MW): results of a prospective, randomized, multicenter phase 3 study (the StiL NHL7\u20132008 MAINTAIN trial). Blood. 2019;134(Supplement_1):343.","journal-title":"Blood"},{"issue":"23","key":"559_CR36","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"Sarah E. M. Herman","year":"2011","unstructured":"Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287\u201396.","journal-title":"Blood"},{"issue":"3","key":"559_CR37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ejh.12427","volume":"94","author":"V Seda","year":"2015","unstructured":"Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2015;94(3):193\u2013205.","journal-title":"Eur J Haematol"},{"issue":"5","key":"559_CR38","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/leu.2016.8","volume":"30","author":"KV Argyropoulos","year":"2016","unstructured":"Argyropoulos KV, Vogel R, Ziegler C, Altan-Bonnet G, Velardi E, Calafiore M, et al. Clonal B cells in Waldenstrom\u2019s macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling. Leukemia. 2016;30(5):1116\u201325.","journal-title":"Leukemia."},{"key":"559_CR39","doi-asserted-by":"crossref","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316.","DOI":"10.1056\/NEJMoa1306220"},{"issue":"15","key":"559_CR40","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"Steven P. Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia. N Engl J Med. 2015;372(15):1430\u201340.","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"559_CR41","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1506192","volume":"373","author":"SP Treon","year":"2015","unstructured":"Treon SP, Xu L, Hunter Z. MYD88 mutations and response to Ibrutinib in Waldenstrom\u2019s macroglobulinemia. N Engl J Med. 2015;373(6):584\u20136.","journal-title":"N Engl J Med"},{"issue":"27","key":"559_CR42","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","volume":"36","author":"Steven P. Treon","year":"2018","unstructured":"Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, et al. Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom macroglobulinemia. J Clin Oncol. 2018;36(27):2755\u201361.","journal-title":"Journal of Clinical Oncology"},{"key":"559_CR43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-3-319-91439-8_7","volume":"212","author":"A Charalambous","year":"2018","unstructured":"Charalambous A, Schwarzbich MA, Witzens-Harig M. Ibrutinib. Recent Results Cancer Res. 2018;212:133\u201368.","journal-title":"Recent Results Cancer Res"},{"key":"559_CR44","first-page":"PS1185","volume":"215492","author":"S Treon","year":"2018","unstructured":"Treon S, Gustine J, Dubeau T, Palomba ML, Advani R, Castillo J. Ibrutinib shows prolonged progression-free survival in symptomatic, previously treated patients with MYD88 mutated Waldenstrom\u2019s macroglobulinemia: long-term follow-up of pivotal trial (NCT01614821). EHA Libr. 2018;215492:PS1185.","journal-title":"EHA Libr"},{"issue":"1","key":"559_CR45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","volume":"29","author":"Y Cao","year":"2014","unstructured":"Cao Y, Hunter ZR, Liu X, Xu L, Yang G, Chen J, et al. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom\u2019s macroglobulinemia. Leukemia. 2015;29(1):169\u201376.","journal-title":"Leukemia"},{"issue":"3","key":"559_CR46","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.16088","volume":"187","author":"Jorge J. Castillo","year":"2019","unstructured":"Castillo JJ, Xu L, Gustine JN, Keezer A, Meid K, Dubeau TE, et al. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019;187(3):356\u201363.","journal-title":"British Journal of Haematology"},{"key":"559_CR47","doi-asserted-by":"crossref","unstructured":"Gustine JN, Xu L, Tsakmaklis N, Demos MG, Kofides A, Chen JG, et al. CXCR4 (S338X) clonality is an important determinant of ibrutinib outcomes in patients with Waldenstrom macroglobulinemia. Blood Adv. 2019;3(19):2800\u20133.","DOI":"10.1182\/bloodadvances.2019000635"},{"issue":"Suppl 1","key":"559_CR48","first-page":"2766","volume":"130","author":"SP Treon","year":"2017","unstructured":"Treon SP, Meid K, Gustine J, Bantilan KS, Dubeau T, Severns P, et al. Long-term follow-up of previously treated patients who received ibrutinib for symptomatic Waldenstrom\u2019s macroglobulinemia: update of pivotal clinical trial. Blood. 2017;130(Suppl 1):2766.","journal-title":"Blood"},{"key":"559_CR49","doi-asserted-by":"crossref","unstructured":"Abeykoon JP, Zanwar S, Ansell SM, Gertz MA, Kumar S, Manske M, et al. Ibrutinib monotherapy outside of clinical trial setting in Waldenstrom macroglobulinaemia: practice patterns, toxicities and outcomes. Br J Haematol. 2019.","DOI":"10.1111\/bjh.16168"},{"issue":"11","key":"559_CR50","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41375-019-0592-8","volume":"33","author":"Jorge J. Castillo","year":"2019","unstructured":"Castillo JJ, Treon SP. What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019.","journal-title":"Leukemia"},{"issue":"12","key":"559_CR51","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","volume":"100","author":"AH Lipsky","year":"2015","unstructured":"Lipsky AH, Farooqui MZ, Tian X, Martyr S, Cullinane AM, Nghiem K, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015;100(12):1571\u20138.","journal-title":"Haematologica."},{"issue":"22","key":"559_CR52","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2217\/fon-2018-0163","volume":"14","author":"CS Tam","year":"2018","unstructured":"Tam CS, LeBlond V, Novotny W, Owen RG, Tedeschi A, Atwal S, et al. A head-to-head phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia. Future Oncol (London, England). 2018;14(22):2229\u201337.","journal-title":"Future Oncol (London, England)"},{"issue":"10121","key":"559_CR53","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(17)33256-7","volume":"391","author":"P Kapoor","year":"2018","unstructured":"Kapoor P, Ansell SM. Acalabrutinib in mantle cell lymphoma. Lancet. 2018;391(10121):633\u20134.","journal-title":"Lancet."},{"issue":"S2","key":"559_CR54","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/hon.2437_58","volume":"35","author":"J Trotman","year":"2017","unstructured":"Trotman J, Opat S, Marlton P, Gottlieb D, Simpson D, Cull G, et al. Bruton\u2019s tyrosine kinase (BTK) inhibitor BGB-3111 demonstrates high very good partial response (VGPR) rate in patients with Waldenstr\u00f6m macroglobulinemia (WM). Hematol Oncol. 2017;35(S2):70\u20131.","journal-title":"Hematol Oncol"},{"key":"559_CR55","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/HS9.0000000000000192","volume":"3","author":"J Trotman","year":"2019","unstructured":"Trotman J, Opat S, Marlton P, Gottlieb D, Simpson D, Cull G, et al. Updated safety and efficacy data in a phase 1\/2 trial of patients with Waldenstr\u00f6m macroglobulinaemia (WM) treated with the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111): PF481. HemaSphere. 2019;3:192\u20133.","journal-title":"HemaSphere."},{"key":"559_CR56","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/j.2572-9241.2019.tb00086.x","volume":"3","author":"M Dimopoulos","year":"2019","unstructured":"Dimopoulos M, Opat S, Lee H-P, Cull G, D'Sa S, Owen R, et al. Major responses in MYD88 wildtype (MYD88WT) Waldenstr\u00f6m macroglobulinemia (WM) patients treated with Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111): PF487. HemaSphere. 2019;3:196.","journal-title":"HemaSphere."},{"issue":"2","key":"559_CR57","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","volume":"18","author":"Meletios A Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom\u2019s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18(2):241\u201350.","journal-title":"The Lancet Oncology"},{"key":"559_CR58","volume-title":"Phase 2 study of tirabrutinib (ONO\/GS-4059), a second-generation Bruton\u2019s tyrosine kinase inhibitor, monotherapy in patients with treatment-naive or relapsed\/refractory Waldenstrom macroglobulinemia","author":"W Munakata","year":"2019","unstructured":"Munakata W. Phase 2 study of tirabrutinib (ONO\/GS-4059), a second-generation Bruton\u2019s tyrosine kinase inhibitor, monotherapy in patients with treatment-naive or relapsed\/refractory Waldenstrom macroglobulinemia. Orlando: ASH; 2019."},{"issue":"18","key":"559_CR59","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","volume":"129","author":"Lian Xu","year":"2017","unstructured":"Xu L, Tsakmaklis N, Yang G, Chen JG, Liu X, Demos M, et al. Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia. Blood. 2017;129(18):2519\u201325.","journal-title":"Blood"},{"issue":"24","key":"559_CR60","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"Jennifer A. Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu T-M, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor Ibrutinib. N Engl J Med. 2014;370(24):2286\u201394.","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"559_CR61","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood-2018-06-860593","volume":"132","author":"Lisa S. Chen","year":"2018","unstructured":"Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018;132(21):2249\u201359.","journal-title":"Blood"},{"issue":"25","key":"559_CR62","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","volume":"378","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Tedeschi A, Trotman J, Garcia-Sanz R, Macdonald D, Leblond V, et al. Phase 3 trial of Ibrutinib plus rituximab in Waldenstrom\u2019s macroglobulinemia. N Engl J Med. 2018;378(25):2399\u2013410.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"559_CR63","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood-2018-99-111178","volume":"132","author":"C Buske","year":"2018","unstructured":"Buske C, Tedeschi A, Trotman J, Garc\u00eda-Sanz R, MacDonald D, Leblond V, et al. Ibrutinib treatment in Waldenstr\u00f6m\u2019s macroglobulinemia: follow-up efficacy and safety from the iNNOVATETM study. Blood. 2018;132(Supplement 1):149.","journal-title":"Blood"},{"issue":"Supplement_1","key":"559_CR64","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2019-130636","volume":"134","author":"G Yang","year":"2019","unstructured":"Yang G, Wang J, Liu X, Munshi M, Chen JG, Kofides A, et al. A novel HCK and BTK dual inhibitor Kin-8194 shows superior activity over ibrutinib and overcomes BTKC481S mediated ibrutinib resistance in vitro and in vivo in MYD88 mutated B-cell lymphomas. Blood. 2019;134(Supplement_1):394.","journal-title":"Blood"},{"key":"559_CR65","doi-asserted-by":"crossref","unstructured":"Fouquet G, Gay F, Boyle E, Bringhen S, Larocca A, Facon T, et al. Treatment of newly diagnosed elderly multiple myeloma. Cancer Treat Res. 2016;169:123\u201343.","DOI":"10.1007\/978-3-319-40320-5_8"},{"issue":"19","key":"559_CR66","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","volume":"122","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Garc\u00eda-Sanz R, Gavriatopoulou M, Morel P, Kyrtsonis M-C, Michalis E, et al. Primary therapy of Waldenstr\u00f6m macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122(19):3276\u201382.","journal-title":"Blood."},{"issue":"4","key":"559_CR67","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2016-09-742411","volume":"129","author":"Maria Gavriatopoulou","year":"2017","unstructured":"Gavriatopoulou M, Garc\u00eda-Sanz R, Kastritis E, Morel P, Kyrtsonis M-C, Michalis E, et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood. 2017;129(4):456\u20139.","journal-title":"Blood"},{"issue":"4","key":"559_CR68","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood-2016-12-754523","volume":"129","author":"P Kapoor","year":"2017","unstructured":"Kapoor P. Another bidder (BDR) revisits. Blood. 2017;129(4):398\u2013400.","journal-title":"Blood"},{"issue":"22","key":"559_CR69","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood.V128.22.618.618","volume":"128","author":"RL Auer","year":"2016","unstructured":"Auer RL, Owen RG, D'Sa S, Pratt G, Popova B, Clifton Hadley L, et al. R2W: subcutaneous bortezomib, cyclophosphamide and rituximab (BCR) versus fludarabine, cyclophosphamide and rituximab (FCR) for initial therapy of Waldenstr\u0151m\u2019s macroglobulinemia: a randomised phase II study. Blood. 2016;128(22):618.","journal-title":"Blood"},{"issue":"Suppl 1","key":"559_CR70","first-page":"2772","volume":"130","author":"K Meid","year":"2017","unstructured":"Meid K, Dubeau T, Severns P, Gustine J, Ghobrial IM, Castillo JJ, et al. Long-term follow-up of a prospective clinical trial of carfilzomib, rituximab and dexamethasone (CaRD) in Waldenstrom\u2019s macroglobulinemia. Blood. 2017;130(Suppl 1):2772.","journal-title":"Blood"},{"issue":"4","key":"559_CR71","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","volume":"124","author":"Steven P. Treon","year":"2014","unstructured":"Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr\u00f6m\u2019s macroglobulinemia. Blood. 2014;124(4):503\u201310.","journal-title":"Blood"},{"key":"559_CR72","doi-asserted-by":"crossref","unstructured":"Castillo JJ, Meid K, Gustine J, Dubeau T, Severns P, Hunter ZR, et al. Prospective clinical trial of ixazomib, dexamethasone and rituximab as primary therapy in Waldenstr\u00f6m macroglobulinemia. Clin Cancer Res. 2018.","DOI":"10.1158\/1078-0432.CCR-18-0152"},{"key":"559_CR73","volume-title":"KEGMCMDDTLDJOFB. Ixazomib, rituximab and dexamethasone (IDR) in patients with relapsed or progressive Waldenstrom macroglobulinemia: results of the prospective phase I\/II HOVON 124\/ECWM-R2 trial","author":"MJ Kersten","year":"2019","unstructured":"Kersten MJ, Minnema M, Vos JM, Nasserinejad K, Kap M. KEGMCMDDTLDJOFB. Ixazomib, rituximab and dexamethasone (IDR) in patients with relapsed or progressive Waldenstrom macroglobulinemia: results of the prospective phase I\/II HOVON 124\/ECWM-R2 trial. Orlando: ASH; 2019."},{"issue":"21","key":"559_CR74","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood.V124.21.1715.1715","volume":"124","author":"DS Siegel","year":"2014","unstructured":"Siegel DS, Kaufman JL, Raje NS, Mikhael JR, Kapoor P, Treon SP, et al. Updated results from a multicenter, open-label, dose-escalation phase 1b\/2 study of single-agent oprozomib in patients with Waldenstr\u00f6m macroglobulinemia (WM). Blood. 2014;124(21):1715.","journal-title":"Blood"},{"issue":"22","key":"559_CR75","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1182\/blood.V128.22.2110.2110","volume":"128","author":"Irene M. Ghobrial","year":"2016","unstructured":"Ghobrial IM, Savona MR, Vij R, Siegel DS, Badros A, Kaufman JL, et al. Final results from a multicenter, open-label, dose-escalation phase 1b\/2 study of single-agent oprozomib in patients with hematologic malignancies. Blood, 2016;128(22):2110.","journal-title":"Blood"},{"issue":"10","key":"559_CR76","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","volume":"128","author":"V Leblond","year":"2016","unstructured":"Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, et al. Treatment recommendations from the Eighth International Workshop on Waldenstrom\u2019s macroglobulinemia. Blood. 2016;128(10):1321\u20138.","journal-title":"Blood."},{"issue":"10","key":"559_CR77","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/17474086.2018.1518129","volume":"11","author":"S Zanwar","year":"2018","unstructured":"Zanwar S, Abeykoon JP, Kapoor P. Ixazomib: a novel drug for multiple myeloma. Expert Rev Hematol. 2018;11(10):761\u201371.","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"559_CR78","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/sonc.2003.50045","volume":"30","author":"GL Nichols","year":"2003","unstructured":"Nichols GL, Stein CA. Modulation of the activity of Bcl-2 in Waldenstrom\u2019s macroglobulinemia using antisense oligonucleotides. Semin Oncol. 2003;30(2):297\u20139.","journal-title":"Semin Oncol"},{"issue":"1","key":"559_CR79","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjh.13278","volume":"170","author":"Yang Cao","year":"2015","unstructured":"Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, et al. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4Wild-type and CXCR4WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015;170(1):134\u20138.","journal-title":"British Journal of Haematology"},{"issue":"Supplement 1","key":"559_CR80","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1182\/blood-2018-99-112325","volume":"132","author":"JJ Castillo","year":"2018","unstructured":"Castillo JJ, Gustine J, Meid K, Dubeau T, Keezer A, Allan JN, et al. Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia. Blood. 2018;132(Supplement 1):2888.","journal-title":"Blood"},{"issue":"22","key":"559_CR81","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood-2015-11-684183","volume":"127","author":"G Knittel","year":"2016","unstructured":"Knittel G, Liedgens P, Korovkina D, Seeger JM, Al-Baldawi Y, Al-Maarri M, et al. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. Blood. 2016;127(22):2732\u201341.","journal-title":"Blood"},{"issue":"3","key":"559_CR82","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","volume":"13","author":"B Vanhaesebroeck","year":"2012","unstructured":"Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13(3):195\u2013203.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"559_CR83","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","volume":"11","author":"B Vanhaesebroeck","year":"2010","unstructured":"Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329\u201341.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"21","key":"559_CR84","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1182\/blood.V122.21.4255.4255","volume":"122","author":"G Yang","year":"2013","unstructured":"Yang G, Liu X, Zhou Y, Xu L, Cao Y, Manning R, et al. PI3K\/AKT pathway is activated by MYD88 L265P and use Of PI3K-delta inhibitors induces robust tumor cell killing in Waldenstrom\u2019s macroglobulinemia. Blood. 2013;122(21):4255.","journal-title":"Blood"},{"issue":"11","key":"559_CR85","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"Ajay K. Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008\u201318.","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"559_CR86","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1080\/10428194.2016.1222380","volume":"58","author":"Jorge J. Castillo","year":"2016","unstructured":"Castillo JJ, Gustine JN, Meid K, Dubeau T, Yang G, Xu L, et al. Idelalisib in Waldenstrom macroglobulinemia: high incidence of hepatotoxicity. Leuk Lymphoma. 2017;58(4):1002\u20134.","journal-title":"Leukemia & Lymphoma"},{"key":"559_CR87","volume-title":"Open label non-randomized phase II study exploring \u201cchemo-free\u201d treatment association with idelalisib+ obinutuzumab in patients with relpased\/refractory (R\/R) Waldenstrom's macroglobulinemia","author":"C Tomowiak","year":"2019","unstructured":"Tomowiak C. Open label non-randomized phase II study exploring \u201cchemo-free\u201d treatment association with idelalisib+ obinutuzumab in patients with relpased\/refractory (R\/R) Waldenstrom's macroglobulinemia. Orlando: ASH; 2019."},{"issue":"8","key":"559_CR88","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","volume":"131","author":"Ian W. Flinn","year":"2018","unstructured":"Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, et al. Duvelisib, a novel oral dual inhibitor of PI3K-delta,gamma, is clinically active in advanced hematologic malignancies. Blood. 2018;131(8):877\u201387.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00559-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-020-00559-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00559-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T22:01:51Z","timestamp":1722376911000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-020-00559-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["559"],"URL":"https:\/\/doi.org\/10.1007\/s11899-020-00559-4","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,31]]},"assertion":[{"value":"31 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}